Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Massachusetts General Hospital
- Study ID
- NCT07014293
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Enhanced Usual Care — OTHERParticipants will receive a singleevaluation with a site social worker along with a list of mental health, social or community resources . This most closely resembles the real-world care available to survivors on an outpatient basis, however, we call this enhanced usual care since proactive identification and referral of posttreatment survivors is not routinely done.
- SMART3RP-Lymphoma — OTHERThe intervention components include: 1. Eliciting the relaxation response (RR) involves sustained mental focus with an attitude of open receptive awareness. 2. CBT to improve stress management involves increasing awareness and identification of the components of one's stress response (negative thoughts, emotions, physical reactions, behaviors, and relational) and learning skills at each session to alter these components (e.g., cognitive restructuring). 3. Positive psychology strategies to achieve growth enhancement focus on utilizing techniques and skills to promote positive growth. Skills focus on increasing social support, positive affect, and compassion.
Study Details
The goal of this clinical trial is to learn if a mind body resilience group program can help increase lymphoma survivors' ability to cope with and manage the challenges that come with the transition into early post treatment survivorship.
Key Dates
- Start date
- Apr 15, 2026
- Status verified
- Mar 2026
- Primary completion
- Jul 1, 2030
- Completion
- Jul 1, 2030
Study Design
- Enrollment
- 254 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Other: Enhanced Usual CareParticipants randomized to EUC will be referred to their site social work team. This most closely resembles the real-world care available to survivors on an outpatient basis. It is an enhanced version of usual care because proactive identification and referral of posttreatment survivors is not routinely done.
- Experimental: SMART3RP-LymphomaParticipants will participate in 8 weekly group sessions, delivered virtually. The intervention components include: 1. Eliciting the relaxation response (RR) involves sustained mental focus with an attitude of open receptive awareness. 2. CBT to improve stress management involves increasing awareness and identification of the components of one's stress response (negative thoughts, emotions, physical reactions, behaviors, and relational) and learning skills at each session to alter these components (e.g., cognitive restructuring). 3. Positive psychology strategies to achieve growth enhancement focus on utilizing techniques and skills to promote positive growth. Skills focus on increasing social support, positive affect, and compassion.
Primary Outcome Measure
Change from Baseline in Coping Scores on the Measure of Current Status Scale (MOCS-A) [ Time Frame: Baseline to 3 month follow up ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mass General Brigham | Boston | Massachusetts | 02114 | Giselle Perez, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Boston, MA
By research site
Related Studies
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Aurora, Colorado
- Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaPHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Miami, Florida
- A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsPHASE1/PHASE2 · Recruiting · Turning Point Therapeutics, Inc. · Los Angeles, California
- UPLYFT For Lymphoma SurvivorsRecruiting · Dana-Farber Cancer Institute · Boston, Massachusetts